Climb Bio (CLYM) Accumulated Expenses (2020 - 2026)

Climb Bio (CLYM) has 7 years of Accumulated Expenses data on file, last reported at $984000.0 in Q1 2026.

• Quarterly Accumulated Expenses fell 83.88% year-over-year to $984000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $984000.0 (down 83.88% YoY) and the FY2025 annual result came in at $4.5 million, up 9.58% from the prior year.
• Accumulated Expenses retreated to $984000.0 in Q1 2026, from $4.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $6.1 million in Q1 2025 to a low of $914000.0 in Q2 2025.
• A 5-year average of $3.4 million and a median of $3.0 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 496.46% — and 2026, when it slumped 83.88%.
• Tracing CLYM's Accumulated Expenses over 5 years: stood at $5.0 million in 2022, then sank by 51.79% to $2.4 million in 2023, then soared by 67.24% to $4.1 million in 2024, then advanced by 9.58% to $4.5 million in 2025, then sank by 77.93% to $984000.0 in 2026.
• The last three Accumulated Expenses figures came in at $984000.0 (Q1 2026), $4.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.